Dermatopharmacokinetics of betamethasone 17-valerate: Influence of formulation viscosity and skin surface cleaning procedure by Wiedersberg, S et al.
        
Citation for published version:
Wiedersberg, S, Leopold, CS & Guy, RH 2009, 'Dermatopharmacokinetics of betamethasone 17-valerate:
Influence of formulation viscosity and skin surface cleaning procedure', European Journal of Pharmaceutics and
Biopharmaceutics, vol. 71, no. 2, pp. 362-366. https://doi.org/10.1016/j.ejpb.2008.10.001
DOI:
10.1016/j.ejpb.2008.10.001
Publication date:
2009
Link to publication
©Elsevier
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 12. May. 2019
Pharmacodynamics and dermatopharmacokinetics of betamethasone 17­
valerate: Assessment of topical bioavailability 
Sandra Wiedersberg*, Aarti Naik+, Claudia S. Leopold§, Richard H. Guy* 
*Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, 

UK. 

+Triskel Integrated Services SA, Geneva, Switzerland.
 
§Institute of Pharmacy, Department of Pharmaceutical Technology, University of
 
Hamburg, Hamburg, Germany. 

Correspondence: R.H. Guy, Department of Pharmacy & Pharmacology, University of
 
Bath, Claverton Down, Bath, BA2 7AY, England, Tel.  +44.1225.384901,  

Fax  +44.1225.386114, E-mail: r.h.guy@bath.ac.uk
 
Short title: Topical drug bioavailability
 
Abbreviations: 

AARC Area above the response curve 
AUC Area under the curve 
BMV Betamethasone 17-valerate 
D/L² Diffusivity parameter 
DPK Dermatopharmacokinetic 
K Stratum corneum-vehicle partitioning coefficient 
LMO Light mineral oil 
MCT Medium chain triglycerides 
ME Microemulsion 
SC Stratum corneum 
TCL Transcutol® 
TG Topical glucocorticoids 
1
 
Summary 
Background: The bioavailability of most topically-delivered drugs is difficult to quantify, 
but is generally believed to be very low.  With the exception of the vasoconstrictor assay 
for corticosteroids, no methodology to quantify the rate and extent of drug delivery to 
the skin has been validated.  Recent research has examined the dermatopharmacokinetic 
(DPK) technique, which is based on stratum corneum (SC) tape-stripping. 
Objective: To compare the in vivo bioavailability of different topical formulations of 
betamethasone 17-valerate (BMV) using the vasoconstrictor assay and the DPK method. 
Methods: BMV was formulated in different vehicles and the drug concentration was 
adjusted to either (i) equal thermodynamic activity, or (ii) a range of values up to that 
corresponding to 80% of maximum thermodynamic activity. Vasoconstriction, an 
accepted and widely-used method to determine bioavailability and bioequivalence of 
topical steroids, was quantified with a chromameter over 24 hours post-removal of the 
formulation.  Drug uptake into the SC was assessed by tape-stripping.   
Results: BMV at the same thermodynamic activity in different vehicles provoked similar 
skin blanching responses, while DPK profiles distinguished between the formulations. 
Further, skin blanching responses and drug uptake into the SC clearly depended upon the 
absolute BMV concentration applied.  However, while the saturable nature of the 
pharmacodynamic response was clear, the tape-stripping method showed distinguished 
unequivocally between different formulations and different concentrations. 
Conclusions: The DPK approach offers a reliable metric with which to quantify transfer of 
drug from the vehicle to the SC, and may be useful for topical bioavailability and 
bioequivalence determinations. 
Key words: corticosteroids, dermatopharmacokinetics, topical bioavailability, topical 
bioequivalence, vasoconstrictor assay  
2
 
The efficiency of topical delivery is notoriously inefficient, with typical bioavailabilities of 
only a few percent of the applied dose.  Rational development of better formulations 
requires better creativity and better methods with which to quantify bioavailability (BA) 
and bioequivalence (BE) of drug delivery to a target in the skin. Topical BA/BE 
evaluation usually requires clinical trials, which are invasive, relatively insensitive, time-
consuming and costly.  In the case of topical glucocorticoids (TG), however, BA/BE can 
be assessed using the vasoconstrictor assay.  In 1995, the U.S. Food and Drug 
Administration (FDA) published a Guidance document for testing BE of different TG 
formulations1.  This Guidance consists of a pilot study to explore the dose duration-
response relationship of a reference listed drug (RLD) and to determine the appropriate 
dose duration for use in a subsequent pivotal test, which then compares the in vivo 
response of the test product with that of the RLD to document whether BE has, or has 
not, been achieved.  
Apart from TG, for all other topical drugs, however, the vasoconstrictor assay is 
not useful to document BA/BE and, at the moment, clinical trials are the only option. 
However, in 1998, evolving from the first quantitative stratum corneum (SC) tape-
stripping experiments2-5, the FDA proposed an alternative, potentially more generally 
applicable, technique instead: the dermatopharmacokinetic approach (DPK), analogous 
to the pharmacokinetic method of oral drug BA/BE assessment6,7 . The DPK approach 
evaluates topically applied drug levels in the SC, the outermost layer of the skin, as a 
function of time post-application and post-removal of the formulation.  The Draft 
Guidance6 allows the assessment of both drug uptake into and drug elimination from the 
SC.  At specific times, layers of the SC are sequentially removed at the treated site with 
adhesive tapes and the total amount of drug is subsequently analyzed therein.  From the 
DPK profile of drug mass in the  SC as a function of time, pharmacokinetic parameters 
such as the area under the curve (AUC), the maximum amount drug in the tape-strips 
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(Amax) and the time (Tmax) at which Amax is attained are deduced and used to characterize 
the local BA. 
The DPK method assumes that SC drug levels are directly related to those in the 
viable epidermis and/or dermis, as the SC is typically the rate-determining barrier to 
percutaneous absorption.  In other words, it is hypothesized that the rate and extent of 
drug disposition in the SC will reflect that achieved at target sites which are further into 
the skin. Indeed, there have been experiments using commercially available TG products 
in which the drug uptake phase into the SC using tape-stripping have been favorably 
compared with the pharmacodynamic response8-11. However, this Draft Guidance was 
withdrawn in 2002, mainly because of doubts regarding reproducibility, flaws resulting 
from the similar design of the approach to oral BE assessment, and criticism that 
quantification of the amount of SC removed should be better controlled12. 
As a consequence, a critical re-evaluation of the DPK method is in progress, with 
a clear objective being to validate a refined approach. Important progress has been 
made with respect to quantification and standardization of the amount of SC removed 
during tape-stripping13,14 such that drug concentration profiles across the membrane can 
now be expressed on the same scale: that is, as a function of the relative position within 
the SC15. Equally, DPK parameters, characterizing drug partitioning and diffusivity into 
and through the SC, can be deduced and used to quantify, respectively, the extent and 
rate of drug delivery.  These advances have been illustrated for terbinafine16-18 and for 
ibuprofen19-22 delivered from different vehicles.  
The goal of this study was to explore the challenge of validating the DPK 
methodology by comparing the assessment of the topical BA of betamethasone 17­
valerate (BMV) using the vasoconstrictor assay and the tape-stripping approach.  With 
respect to the latter method, the protocol specified in the Draft Guidance6 was compared 
to alternative procedures introduced more recently18-22.  The sensitivity of the 
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techniques, and their ability to discriminate between different formulations, was 
examined as a function of the applied drug concentration and thermodynamic activity (a 
measure of the drug’s so-called ‘leaving tendency’ from the vehicle and is related to its 
solubility). 
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Materials & Methods 
Formulations 
Betamethasone 17-valerate (BMV) (Crystal Pharma, Boecillo, Spain) was 
dissolved in (i) the reference vehicle, medium chain triglycerides (MCT) (Mygliol 812N, 
Synopharm, Barsbüttel, Germany), and in (ii) light mineral oil (LMO) (Synopharm), (iii) 
the microemulsion Mikro 100® (ME) (Sebapharma, Boppard, Germany), and (iv) 
Transcutol® P (TCL) (Gattefossé, Saint Priest, France), as test vehicles.  The components 
of the ME were aqua, polysorbate 20, polyglyceryl-6 dioleate, ethylhexyl cocoate, PEG-8 
caprylic/capric glycerides, denatured alcohol, tocopheryl acetate, ectoin, panthenol, 
centella asiatica, ethoxydiglycol oleate, sodium lactate, parfum and phenoxyethanol.  To 
avoid spreading of the formulations on the skin, either 15% (w/w) polypropylene 
(Sigma-Aldrich, Steinheim, Germany) or 10% (w/w) Aerosil® 200 (Sigma-Aldrich) was 
used to thicken the vehicles into semi-solid gels.  The formulations studied, although not 
as complex as many commercialized products, provided reasonable models for those in 
clinical use and were able to solubilize BMV over a wide range of concentrations. 
The saturation level (Cs,V) of BMV in each vehicle was determined by stirring a 
suspension of the drug in the liquid vehicles at 32°C until equilibrium was attained (about 
72 hours).  The samples were centrifuged, diluted either with acetonitrile alone or with 
acetonitrile/water 60:40 (v/v) and analyzed by liquid chromatography (see method 
below).  Because of the incompatibility of LMO with acetonitrile, the saturation level of 
BMV in this excipient was determined using the iterative method of visual clouding.  The 
experiments were performed in triplicate. 
In the first part of the study, the BMV concentration was adjusted to 80% of 
saturation in each vehicle to provide the drug at equivalent thermodynamic activity 
(Table 1). This means that the “leaving tendency” of the drug from these formulations 
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was 80% of that from a vehicle in which BMV is present as a suspension, i.e., a saturated 
solution (the case for many of the ointment and cream products in clinical use). 
Table 1: Saturation level (Cs,V) of BMV in different vehicles at 32°C (mean ± SD, n = 3). 
Vehicle Cs,V [mg mL-1] 
LMO 0.0021 ± 0.0003 
MCT 2.1 ± 0.2 
ME 11.7 ± 0.4 
TCL 126 ± 1.1 
In the second component of the investigation, only the MCT and ME vehicles were 
evaluated and the BMV concentration was adjusted to different degrees of its saturation 
level (Table 2).  
Table 2: Thermodynamic activities of BMV, expressed as degree of saturation (Cs,V), and 
concentrations (CV) studied in the second set of experiments using ME and MCT 
formulations only. 
Degree of Cs,V 0.80 0.10 0.05 0.026 0.013 0.0064 0.0032 
CV ME [mg mL-1] 9.3 1.2 0.6 0.3 0.15 0.07 0.04 
CV MCT [mg mL-1] 1.7 0.2 - - 0.027 0.013 -
MCT was chosen as the reference vehicle as it was not expected to have any  
effect on skin barrier function per se23. BMV was selected as a typical, and frequently 
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used, class 2 TG24.  BMV has a relatively high molecular weight (476.6 Da) and is quite 
lipophilic (log(octanol/water partition coefficient) = 3.78). 
Vasoconstrictor assay 
Twelve healthy Caucasian volunteers (8 female, 4 male), aged 21-55 years, from 
whom informed consent was obtained, participated in the two studies, which were 
approved by the Ethics Committee of the University of Leipzig.  The study followed the 
“staggered application with synchronized removal” method of the FDA Guidance “Topical 
Dermatologic Glucocorticosteroids – In vivo Bioequivalence”1.  250 µl of each formulation 
were applied in a 1.2 cm diameter Hill Top Chamber® (Hill Top Research, Cincinnati, OH, 
USA) which was affixed with adhesive tape.  Although the amount of formulation applied 
was greater than that which would be used clinically, this infinite ‘dose’ ensured that drug 
depletion from the vehicle (either via absorption into the skin or adsorption onto the Hill 
Top chamber®) could be ignored when the data were subsequently interpreted.  The drug 
application sites were on the volar forearm, at least 4 cm from the wrist and 4 cm from 
the antecubital fossa. Because of the known circadian activity of TG, all formulations 
were applied only at 0800 hours. 
In the first part of the study, LMO, ME and TCL were compared with the reference 
vehicle, MCT.  The formulations, as well the drug-free vehicles as control, were applied to 
the skin for dose durations of 2, 3, 4, 5 and 6 hours.  The chambers were then removed 
and excess formulation was cleaned off with a dry paper towel.  The skin blanching 
response was assessed with a chromameter (CR-300, Minolta, Ahrensburg, Germany) 
using the a-scale values at various times up to 24 hours following formulation removal 
(Figure 1 ).  Baseline readings were taken at all sites prior to the application of the 
formulations. The a-scale readings for each drug application site were adjusted for the 
baseline value and the control and expressed as the change in this parameter (Δa). As 
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 the a-scale values decrease with increasing skin blanching, Δa is negative. The degree of 
response was therefore expressed as the (positive) area above the response curve 
(AARC) using the trapezoidal rule. 
BL Formulation Application and Removal
BL
Skin Blanching MeasurementsBL

BL

BL

-7 -6 -5 -4 -3 -2 -1 0 0 2 4 6 8  10  12  14  16  18  20  22  24  
Hours Before Formulation Removal Hours After Formulation Removal 
Figure 1: Vasoconstriction experimental protocol. Staggered application with 
synchronized removal: schematic representation of the pilot study protocol, BL = 
Baseline1 . 
In the second series of experiments, BMV, at different degrees of saturation in 
MCT and ME (Table 2), were applied to the forearm for 4 hours. This dose duration was 
chosen to be sure that the blanching response would be quantifiable for all 
concentrations applied.  After removal of the formulations, the skin blanching response 
was assessed as before over the 24 hour period after formulation removal. 
Tape-stripping experiments 
Six healthy Caucasian volunteers (4 female, 2 male, 23-41 years) with no history 
of dermatological disease participated in these measurements, which were approved by 
the Salisbury and South Wiltshire Research Ethics Committee. Written consent was 
obtained from all subjects. 
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A single (and again) infinite dose volume of 600 µL of each BMV formulation was 
first applied using a 1.8 cm diameter Hill Top Chamber® on the volar aspect of the 
forearm. After a 2-hour application (dose duration), the chambers were removed and 
excess formulation was cleaned off with a dry paper towel.  The application time was 
selected based on earlier work20,21 . Immediately after cleaning, the SC at the treated 
site was progressively removed by repeated adhesive tape-stripping (Scotch Book Tape, 
3M, St. Paul, MN, USA).  A piece of polypropylene foil with a predefined hole was placed 
onto the cleaned, treated skin site and affixed with self-adhesive tape.  This template 
ensured that all tape-stripping procedures took place at the same site (and eliminated 
any potential problems created by the formulation spreading over the skin). The tape 
(2.5 x 2.5 cm) was applied over this template, using a constant pressure (140 g cm-2) 
via a weighted roller and then removed.  Up to 20 strips were taken from each site, but 
the SC was never completely removed.  To ascertain the remaining skin barrier function, 
transepidermal water loss (TEWL) measurements were performed (AquaFlux V4.7, Biox 
Systems Ltd., London, UK) during the stripping procedure, which was stopped when 
TEWL reached ~4 times its initial value or 60 g m-2 h-1. Each tape was carefully weighed 
before and after stripping on a 10-µg precision balance (Mettler AT 261, Greifensee, 
Switzerland) to determine the mass of SC removed.  From this mass, the known stripped 
area, and given that the density of the SC is ~1 g mL-1 25, it was possible to calculate the 
SC thickness removed on each tape-strip, and hence the corresponding position within 
the barrier26. BMV in the tape-strips was subsequently extracted quantitatively and 
analyzed by liquid chromatography (see method below).  The amount of BMV on each 
strip was then converted to a concentration at a specific depth into the SC.  Although the 
gravimetric approach to determine the amount of SC removed on each strip is labor-
intensive, the method remains, for the moment, the ‘gold-standard’ against which 
alternative procedures, such as those based on protein quantification27,28, are calibrated. 
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To calculate the total thickness of the SC (L), the same tape-stripping procedure 
was performed at an adjacent, untreated skin area with measurements of TEWL after 
each tape-strip26. The amount of SC removed on each tape was again determined 
gravimetrically and converted into a SC thickness removed on each strip.  It was then 
possible to calculate the total thickness of the SC from the x-intercept of a graph of 
TEWL-1 versus the cumulative thickness of SC removed26.  Knowing the SC thickness of 
each subject made it possible to express all BMV concentration profiles as a common 
function of the relative position (depth) into the SC, greatly facilitating objective 
comparison of the results15,29 . 
A second DPK study was then carried out according to the FDA Draft Guidance6. 
Six human volunteers (all female, aged 25-32 years), in good general health and with no 
history of dermatological disease, participated in these experiments.  The same infinite 
volume of either the MCT or ME formulation (containing drug at 80% of its saturation 
level) was placed in a 1.2 cm diameter Hill Top Chamber® and affixed via an adhesive 
tape to the volar forearm.  A maximum of six chambers, three with the MCT formulation 
and three with the ME, were applied (Figure 2).  For drug uptake, the formulations were 
applied to the left forearm and the SC samples were collected from each site immediately 
after removal of the chambers at 2, 4 and 6 hours. To assess drug elimination, the 
formulations were applied to the right forearm, and maintained in place for 6 hours. All 
formulations were then removed (using dry paper swabs) and SC samples were taken 
after a further 2, 6 and 24 hours. 
Each treated skin site was initially tape-stripped 12 times; additional tape-strips 
were taken, if necessary, until the value of transepidermal water loss (TEWL) was ~4­
fold greater then the pre-stripping value measured at an adjacent skin site and untreated 
with either formulation.  Periodic measurements of TEWL, before and after the stripping 
process, were performed.  A 4-fold increase in the TEWL value should have ensured that 
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at least 75% of the SC was removed at each skin site15. The first tape-strip was 
discarded to avoid potential residual drug contamination.  The drug on the remaining 
tape-strips was subsequently extracted and analyzed by HPLC (see method below). The 
total amount of BMV recovered from the tape-strips was expressed in micrograms per 
square centimeter (µg cm-2). 
R12 R30 
T12 T30 
R8 
T8 
R4 R6 
T4 T6 
R2 
T2 
left
right
Figure 2: Dermatopharmacokinetic application scheme according to the Draft 
Guidance6. T = test vehicle (ME), R = reference vehicle (MCT). Uptake phase 2 to 6 
hours �; elimination phase 8 to 30 hours �. 
Extraction and analysis of BMV 
Each tape from the first DPK study was completely extracted by overnight shaking 
with 1.0 mL of 60:40 (v/v) acetonitrile/water (Sigma-Aldrich, Steinheim, Germany). 
Tapes from the second set of measurements were extracted in groups of 5 or fewer. 
Validation of the extraction procedure involved spiking tape-stripped samples of 
untreated SC with a known quantity of BMV. Recovery was 96.9 ± 3.4 % (n = 5). BMV 
in the various samples was quantified by high-performance liquid chromatography 
(HPLC) analysis (Dionex, Munich, Germany) using a Lichrospher® 100 RP-18 (4 x 125 
12
 
mm) column (Hichrom, Reading, UK) with UV detection at 240 nm. The mobile phase 
was degassed acetonitrile/deionized water (60:40 v/v) and was delivered at a flow rate 
of 1 mL min-1 in a 50-µL sample loop.  The retention time of BMV at 25°C was ~3.8 
minutes. BMV was determined using the area under the curve method and calibration 
plots were generated with the neat compound (R² = 0.999).  The limit of quantification 
was 0.1 µg mL-1. 
Statistics 
Statistical data analysis was performed using paired two-tailed Student’s t-tests 
and a one- and two-way Analysis of Variance (ANOVA).  P-values less than 0.05 were 
considered statistically significant. 
Analysis of the concentration profile data 
The SC distribution profiles of BMV (i.e. drug concentration (Cx) as a function of 
position (x) within the SC and time (t)) were fitted to the appropriate solution of Fick’s 
second law of diffusion30: 
⎡ x 2 1 x D 2 2 ⎤Cx = KCV 1− − ∑
∞ 
sin(nπ )exp(− 2 n π t)    Eq.  1  ⎢⎣ L π n=1n L L ⎥⎦ 
where CV is the BMV concentration in the vehicle, K is the apparent partition coefficient of 
BMV between the SC and the applied vehicle, and D is the diffusivity of the drug in the 
SC of total thickness L. 
The analysis assumes the following boundary conditions: (i) at the skin surface (x 
= 0), for the entire duration of the experiment, the BMV concentration is K•CV; (ii) at t = 
0, the SC contains no drug; and (iii) at the inner surface of the SC (x = L), perfect ‘sink’ 
conditions exist for the drug. 
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Fitting the experimental data from the first set of tape-stripping experiments to 
Eq. 1 (using GraphPad Prism® 4.03 Software, San Diego, CA, USA) allowed estimates of 
K and D/L² to be derived.  The latter has units of a first-order rate constant (time-1), and 
is a ‘classic’ diffusion parameter derived from these experiments31. In terms of topical 
BA, K reports on the extent of drug delivery, while D/L2 reflects information about the 
rate of uptake into the SC.  Integration of Eq. 1 yields the area under the drug 
concentration profile (area under the curve, AUC) in units of amount per volume: 
1 ⎛ x ⎞ ⎡ 1 4 ∞ 1 ⎛ D 2 2 ⎞⎤AUC = C d⎜ ⎟ = KC − ∑ exp⎜− (2n + 1) π t⎟ Eq. 2 ∫ x V ⎢ 2 2 2 ⎥
0 ⎝ L ⎠ ⎣2 π n=0(2n + 1) ⎝ L ⎠⎦ 
As the SC thickness (L) was independently determined, it was further possible to 
evaluate the total amount (A) of BMV in the barrier in units of amount per unit area via 
the simple conversion: 
A = AUC ⋅L          Eq.  3  
In this way, from the K and D/L2 values in the initial series of experiments, it was 
possible to predict the values of A as a function of time in the second set of DPK 
measurements. 
Finally, using the “elimination phase” (6-30 hours) results from the second series 
of tape-stripping experiments, an effective elimination rate constant (ke) of BMV from the 
SC was determined assuming a mono-exponential, first-order decay: 
A = A ⋅ exp[− k ⋅ (t − 6)] Eq. 4 6−30 6 e 
where A6 is the amount per unit area of drug in the SC at 6 hours. 
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Results  
Influence of vehicle and dose duration on skin blanching  
The mean blanching response versus time profiles, as a function of dose duration 
and vehicle, are shown in Figure 3.  BMV was applied at the same thermodynamic 
activity (80% of saturation) in each vehicle.  The chromameter readings were baseline-
adjusted and untreated control site corrected and are expressed as Δa values. The 
blanching response increased with time for all formulations post-removal reaching a 
maximum 4-6 hours later.  It would appear, therefore, that drug taken up into the SC 
during the application period was still being released to the site of vasoconstrictive 
response post-removal of the delivery system, a manifestation of the phenomenon often 
referred to, in the literature, as a ‘reservoir’ effect2,3,32-35 . 
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Figure 3: Corticosteroid-induced skin blanching.  Vasoconstriction response (Δa) versus 
time profiles provoked by BMV delivered in MCT, LMO, ME and TCL following dose 
durations of 2-h , 4-h  and 6-h ● (mean ± SD; n = 6).  For clarity of viewing, some 
data have been slightly displaced on the time-axis and only +SD and –SD are shown for 
the 2-h and 6-h results, respectively. 
The skin blanching response increased with increasing dose duration.  Analysis of 
variance indicated that both the vehicle and the dose duration had a significant influence 
on the AARC values (P < 0.05, two-way ANOVA).  Figure 4 summarizes these results and 
shows clearly that the drug delivered from LMO shows the lowest pharmacodynamic 
response at all investigated dose durations.  On the other hand, the blanching response 
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profiles induced by BMV delivered from MCT, ME and TCL were similar, and not 
significantly different from each other.  While these latter findings would be consistent 
with the anticipated equivalence of delivery from vehicles containing the drug at similar 
thermodynamic activities, the poorer performance of LMO, which was not seen in earlier 
work36, suggests that this formulation is retarding BMV transport in some way.  However, 
because these conclusions are based on measurements of a pharmacodynamic response, 
which is known to be saturable, an independent approach (namely, the tape-stripping 
component of this work described below) to evaluate drug delivery is desirable. 
MCT 
60 LMO 
ME 
40
A
A
R
C
** ** 
TCL 
20 ** 
0 
2 3 4 5 6 
Dose duration [h] 
Figure 4: Skin blanching depends on steroid formulation.  AARC values derived from the 
vasoconstriction response profiles as a function of dose duration and vehicle (mean ± 
SD, n = 6).  Significant differences (P < 0.01) relative to the reference formulation (MCT) 
are shown by the double asterisks. 
Influence of vehicle on drug uptake into SC 
Uptake of BMV from the different vehicles into the SC, determined by tape-
stripping, yielded the results collected in Figure 5 for MCT (the reference formulation), 
ME and TCL.  Data from LMO could not be obtained because the levels of drug extracted 
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from the tape-strips were below the BMV assay’s limit of quantification.  Fitting Eq. 1 to 
the profiles generated individual values of K and D/L² parameters, the means (± SD) of 
which are in Table 1.  AUC values were calculated from these parameters using Eq. 2 and 
are also included in Table 1. BMV delivery was significantly different between all 
formulations with TCL > ME > MCT (ANOVA, p < 0.05).  In terms of AUC, TCL out­
performed  MCT by a factor of more than 60-fold, while ME achieved a 5-fold  
improvement relative to the reference formulation.  Interestingly, the values of K and 
D/L² deduced from the concentration profiles were not significantly different between 
MCT, ME and TCL (Table 3).  In contrast, the deduced saturation concentrations of BMV 
in the SC (Cs,SC) were highly vehicle-dependent implying that components of the ME and 
TCL formulations had also been taken up into the SC in sufficient quantities to alter the 
drug’s solubility in the barrier.  Such behavior has been previously reported for 
Transcutol® 37-39 and for other cosolvents, such as propylene glycol22,40 . 
It is noteworthy that the values of K derived from these experiments are not far 
removed from unity. We have observed not dissimilar behavior in recent work as well19­
22. While an unequivocal explanation for this phenomenon cannot be offered at this time, 
it is possible that the formulation almost ‘overwhelms’ the outermost layer of the SC, 
such that partitioning occurs between two rather similar phases as a result.  Further 
experiments are required to shed further light on this issue. The similarity in the values 
of D/L2 indicate that excipients from the formulations did not significantly promote or 
retard BMV diffusion across the SC (as has been seen before, for example, when 
terbinafine was administered in a vehicle containing the known penetration enhancer, 
oleic acid16).  The absolute values of D/L2 for BMV are somewhat smaller than those 
which have been reported for ibuprofen19-22, consistent with the larger molecular weight 
of the corticosteroid. 
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Figure 5: Dermatopharmacokinetic profiles depend on steroid formulation.  BMV 
concentration versus normalized depth into the SC following a 2-hour application of the 
drug at 80% of saturation in three different vehicles: MCT, ME and TCL. The individual 
profiles from 6 volunteers are shown, together with the best fits to the data of Eq. 1. 
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Table 3: Tape-stripping experimental results (mean ± SD, n = 6) for BMV delivered 
from 4 vehicles following a 2-hour application.  The drug concentration in each vehicle 
(CV) equalled 80% of its saturation level. 
Vehicle 
CV 
[mg mL-1] 
Ka D/L2 
[h-1]a 
Cs,SC 
[mg mL-1]b 
AUC 
[mg cm-3]c 
A 
[µg cm-2]d 
MCT 1.7 0.83±0.24 0.058±0.013 1.68±0.49* 0.51±0.18* 0.77±0.40* 
ME 9.3 0.78±0.10 0.056±0.021 9.13±1.15* 2.61±0.67* 3.73±1.40* 
TCL 100.8 1.04±0.24 0.042±0.028 131±30.8* 32.5±13.3* 38.0±17.5* 
LMO 0.0017 n.d.e n.d.e - n.d.e n.d.e 
a Obtained by fitting experimental data to Eq. 1. 

b Cs,SC = K·Cs,V. 

c From Eq. 2 using the corresponding value of K and D/L2. 

d From Eq. 3 using the corresponding, independently-determined values of L.
 
e Not determined as BMV could not be quantified in tape-strip extracts. 

* Significantly different from each other (p < 0.05). 
Influence of drug concentration applied on skin blanching  
The first series of vasoconstrictor experiments, taken together with the tape-
stripping results, intimated that the pharmacodynamic response had become saturated 
when BMV was applied at 80% of its maximum thermodynamic activity.  Therefore, a 
second set of experiments was performed, using the MCT and ME formulations, to 
examine skin blanching when the drug was administered at lower doses.  A single dose 
duration of 4 hours was chosen and the vasoconstriction was followed over the next 24 
hours. The results show that the response is indeed concentration-dependent, as has 
been previously suggested41. Figure 6 expresses the data in terms of the AARC as a 
function of both the BMV concentration in the vehicle and its degree of saturation. 
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Because the concentrations employed vary over three orders of magnitude, the data 
have been plotted with a logarithmic x-axis in the normal way.  It is clear that the AARC 
did not increase over the last log unit of concentration (from 1 to 10 mg mL-1), 
suggesting that the response was indeed saturated; in contrast, up to ~1 mg mL-1, AARC 
increased log-linearly with concentration. 
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Figure 6: Skin blanching dose-response behaviour.  AARC values derived from the 
vasoconstriction profiles as a function of (A) BMV concentration (CV), and (B) degree of 
saturation in the vehicles studied (MCT () and ME (о)) following a 4-hour application 
(mean ± SD, n = 6). 
Influence of drug concentration applied on uptake into the SC 
It was then logical to determine whether BMV delivery into the SC showed a 
concentration dependence and to determine the nature of the relationship.  Again, using 
the MCT and ME vehicles, the SC uptake of drug was evaluated as a function of 
concentration in the formulation.  The results, following a 2-hour application are 
summarized in Figure 7 (and Figure 5) and Table 4. 
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Figure 7: Dermatopharmacokinetic dose-response behavior.  BMV concentration versus 
normalized depth into the SC following a 2-hour application of the drug in MCT and ME at 
different concentrations.  The individual profiles from 6 volunteers are shown, together 
with the best fits of the data to Eq. 1. 
The lowest concentrations considered were those that resulted in quantifiable 
amounts of drug in the tape-strips; for this reason, only one other MCT formulation was 
studied while two others were possible for ME. 
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Table 4: Tape-stripping experimental results (mean ± SD, n = 6) for BMV delivered 
from MCT and ME following a 2-hour application.  The drug concentrations in each vehicle 
(CV) were modified to significantly alter the BMV thermodynamic activity. 
Vehicle CV 
[mg mL-1] 
Degree of 
Cs,V 
Ka D/L2 
[h-1]a 
Cs,SC 
[mg mL-1]b 
AUC 
[mg cm-3]c 
MCT 1.7 0.80 0.83±0.24 0.058±0.013 1.68±0.49 0.51±0.18 
 0.21 0.10 0.80±0.29 0.036±0.020 1.69±0.61 0.05±0.02* 
ME 9.3 0.80 0.78±0.10 0.056±0.021 9.13±1.15 2.61±0.67 
 1.2 0.10 0.58±0.11 0.025±0.016 6.81±1.30 0.17±0.08*
 0.15 0.013 0.59±0.33 0.042±0.024 6.95±3.96 0.03±0.01* 
a Obtained by fitting experimental data to Eq. 1.
 
b Cs,SC = K·Cs,V. 

c From Eq. 2 using the corresponding value of K and D/L2. 

* Significantly different from the corresponding value at 0.80•Cs,V (p < 0.05). 
It is first noted that the estimated values of K and D/L2 were not significantly 
different from those derived from the results for the vehicles which contained BMV at 
80% of its saturation level (Table 4).  In contrast, the AUC values were decreased when 
the drug was applied at lower concentrations, with the reductions observed being more 
or less proportional to the corresponding change in BMV thermodynamic activity.  For 
example, an 8-fold decrease in BMV level in the MCT vehicle resulted in an approximately 
order of magnitude reduction in AUC; similarly, when the drug concentration in ME was 
lowered by ~60-fold, the AUC decreased by about a factor of 80.  It follows that, unlike 
the skin blanching response, drug uptake into the SC from a vehicle, in which the 
compound is below its solubility, is not saturable. 
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This point is reinforced when the AARC derived from the vasoconstriction response 
profile is plotted against the SC uptake AUC determined by tape-stripping (Figure 8). 
When all relevant data are included (i.e., one concentration for TCL, two for MCT and 
three for ME), it is clear that the delivery of BMV into the SC is affected by both the  
thermodynamic activity of the drug and by specific vehicle-skin interactions. No evidence 
for saturation of the barrier can be identified.  In contrast, despite a nearly three order 
change in AUC, the vasoconstriction response changed by less than a factor of 10 and 
appears saturable. This may be due to a straightforward pharmacological effect; 
alternatively, the perceived saturation may be the result of the limited solubility of the 
steroid in the region where the receptors are located.  However, distinguishing these (or 
other possibilities) is beyond the scope of the present work. 
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Figure 8: Skin blanching versus dermatopharmacokinetics.  AARC values derived from 
the vasoconstriction profiles (determined after a 4-hour dose duration) plotted against 
the corresponding AUC values for SC uptake determined by tape-stripping after a 2-hour 
application.  Data for BMV delivered from MCT (), ME () and TCL (S) are shown 
(mean ± SD, n = 6). 
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Comparison with Draft Guidance DPK protocol 
Finally, Figure 9A compares the DPK profiles of BMV delivered from MCT and ME 
following the Draft Guidance protocol6.  Significant differences in the amount of drug in 
the SC were observed at all time points between the two vehicles.  ME was clearly the 
more effective formulation.  At 6 hours, SC uptake of BMV from the ME was about 6 µg 
cm-2, compared to only 1 µg cm-2 from the MCT formulation.  The corresponding BA 
parameter Amax reflects this observation, and differed significantly between the two 
vehicles (1.15 ± 0.32 and 7.92 ± 1.50 µg cm-2 for MCT and ME, respectively; P < 0.05). 
The ratio of AUC values (ME/MCT) was 5.05 ± 1.25.  The Tmax values for the two vehicles 
(5.7 ± 0.8 h for MCT, 4.3 ± 2.0 h for ME) were not significantly different, on the other 
hand. When the elimination phase of the DPK profiles was fitted to Eq. 4, no difference 
in the effective elimination rate constant (ke) values was found: 0.04 ± 0.02 and 0.06 ± 
0.02 h-1 for MCT and ME, respectively.  Furthermore, it is worth noting that these 
absolute values are numerically very similar to the D/L2 results reported in Tables 3 and 
4. 
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Figure 9: Refined dermatopharmacokinetic approach for topical BA/BE assessment.  A -
DPK profiles (amount of BMV versus time) of reference (MCT ) and test (ME o) 
formulations (mean ± SD, n = 6).  For the uptake phase, formulations were removed at 
2, 4 and 6 hours. For the elimination phase, formulations were maintained to the skin 
for 6 hours, subsequently removed, and the SC was stripped after a further 2, 6 and 24 
hours. B – Experimentally measured and predicted (using Eqs 2 and 3, and the values of 
K and D/L2, with their respective variances, determined from the first series of tape-
stripping studies) amounts of BMV in the SC, delivered from ME and MCT, during the 
uptake phase of the DPK experiment. 
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Interestingly, it was possible to use the values of K and D/L2 derived from the 2­
hour experiment in the first series of tape-stripping studies to predict the amounts (A) of 
BMV in the SC from Eqs. 2 and 3 during the uptake, or ‘absorption’, phase of the 
experiment (i.e., up to 6 hours when the formulation was removed).  Figure 9B compares 
the experimental and predicted values, which agree very well for MCT, and differ 
insignificantly (by less than a factor of 2) for ME.  As suggested by recent work21, 
therefore, it may be possible to significantly simplify a DPK-type bioequivalence study, in 
terms of the number of time points required to characterize uptake and elimination 
phases, relative to that outlined in the original Draft Guidance6. 
In conclusion, this work demonstrates that the evaluation of topical BA is complex 
and may be sensitive to the methodology employed.  While the vasoconstrictor assay has 
been employed extensively for corticosteroids, the saturable nature of the response 
means that results from such experiments must be analyzed with care (as indeed they 
have been in most occasions in the past).  The tape-stripping, or DPK approach, would 
appear to offer a reliable metric with which to quantify transfer of drug from the vehicle 
to the SC.  The critical validation of this measure to clinical outcome remains a long-term 
objective that will probably be achieved on a case by case (or drug class by drug class) 
basis. Methodological questions remain here as well; for example, the SC recoveries are 
dependent upon the surface cleaning procedure at the end of the application period being 
both efficient and benign (i.e., not encouraging penetration).  Further work is essential to 
explore this question, in particular the potential significance of formulation which may 
become entrapped in skin ‘furrows’ and erroneously considered to be absorbed. 
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